Nanoparticles refer to particles with a particle size between 1-100 nm. Due to its unique microstructure, nanoparticles have the characteristics of volume effect, surface effect, quantum size effect and macroscopic quantum tunneling effect. This allows nanoparticles to be used in in vivo delivery systems. Currently, several nanoparticle-based technologies have been successfully used for gene delivery in vivo, including chemically synthesized nanoparticles, inorganic nanoparticles (gold, silica, calcium phosphate), and quantum dots composed of nanotubes or nanorods.

Nanoparticle transfection typically uses small metal particles or silica as a carrier to deliver nucleic acids into cells. Studies have shown that nanoparticles can be used for transfection of cancer cell lines, primary culture, and tissue-targeted and in vivo delivery.

Figure 1. Schematization of nanoparticle-based gene therapy in vivo.(Chen J, et al.; 2016)

The difficulty of in vivo delivery is the delivery of nucleic acid into cells of a given tissue. Nanoparticles can provide the necessary framework and stability to become an efficient gene delivery system. By changing the size and shape of the nanoparticles, the surface of the nanoparticles can be functionalized to obtain targeted and controlled release capabilities.

In addition, due to differences in cell type morphology and structure, some cells are easy to transfect, while others are relatively difficult. Nanoparticles provide new transfection ideas for these special types of cells. Due to its ultraminiaturized size, nanoparticle-based delivery systems are widely used in RNAi therapy and cancer gene therapy research, and its ability to deliver exogenous nucleic acids into cells is also widely recognized.

As carriers for delivering nucleic acids, positively charged nanoparticles and negatively charged nucleic acids form complexes through ionic interactions on the surface. After surface modification at a later stage, after adding specific tissue-targeting ligands, a nanoparticle in vivo delivery system can be obtained. The system can deliver nucleic acids into specific cells in vivo. Positively charged cations adsorb on negatively charged cell surfaces and are then taken up by cells. Over time, nanoparticles entering cells are degraded and nucleic acids are released into the cytoplasm to perform their functions.

CD BioSciences' nanoparticle-based in vivo Transfection Reagent is a unique, chemically engineered nanoparticle free of animal origin. In addition, we optimize the efficiency of in vivo delivery of siRNA, shRNA, miRNA and plasmid DNA. Our nanoparticle transfection kits, which can be administered systemically or locally in mice, ensure efficient delivery of nucleic acids into heart, lung, liver, pancreas, kidney, and many types of tumor cells.

Advantages of our Nanoparticles as transfection vehicles:

1.  It can enhance the adsorption capacity of the delivery carrier on the cell membrane, thereby improving the uptake of cells;

2.  Low toxicity in vivo, safe to use;

3.  Non-lipid formula, allowing stable complex injection;

4.  Nanoparticle carriers can protect nucleic acids from degradation during in vivo delivery;

5.  Can target specific tissues and cells;

6.  Completely free of animal-derived serum and protein;

7.  Allows for sustained knockout effects after a single injection

8.  Target different organs through different routes of administration.

Our Service:

• Customized nanoparticle transfection kits according to customer needs
• Provide nanoparticle carriers of various materials for users to choose
• Offers vector screening services to identify optimal in vivo transfection vectors
• Professional design and service team to provide you with reliable service and technical support
• Timely feedback of technical reports

CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved.

Reference

1. Chen J, et al.; Production and clinical development of nanoparticles for gene delivery. Mol Ther Methods Clin Dev. 2016, 3:16023.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.